# A Study of Revaree Plus in People With Breast Cancer

> **NCT07042581** · PHASE4 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- Stage 0 Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer
- Stage 0 Breast Carcinoma
- Stage II Breast Carcinoma
- Stage III Breast Carcinoma
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Revaree Plus

## Key facts

- **NCT ID:** NCT07042581
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2029-06-20
- **Final completion:** 2029-06-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07042581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07042581, "A Study of Revaree Plus in People With Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07042581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*